Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Medivation

Share:
Related MDVN
In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated
Here Are All The Big Biotech Mergers In 2016
Biotech Forum Daily Digest: Mylan Adjusts Course, Who Is Next Midcap Buyout Target After Medivation? Spotlight On NeuroDerm (Seeking Alpha)

In a report published Monday, Jefferies & Company reiterated its Buy rating on Medivation (NASDAQ: MDVN), and slightly raised its price target from $61.00 to $62.00.

Jefferies noted, “Following the strong Xtandi beat on 2 wks of sales in Sep and guidance for 4Q12-1Q13 announced by Astellas 2 wks ago, MDVN provided incremental commentary during its Q3 earnings on inventory, 3rd party Rx data, ongoing Xtandi clinical trials and PnL nuts & bolts. We continue to believe in a strong Xtandi launch and have ramped up our initial sales trajectory, offset by higher spend to support a new PT of $62.”

Medivation closed on Friday at $45.70.

Latest Ratings for MDVN

DateFirmActionFromTo
Aug 2016BMO CapitalMaintainsMarket Perform
Aug 2016CitigroupDowngradesBuyHold
Aug 2016Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MDVN)

View Comments and Join the Discussion!